PerturbAI announced the public release of an in vivo Perturb‑seq CRISPR atlas mapping gene function across 8 million brain cells and emerged from stealth with undisclosed pre‑seed funding. The dataset, created with partners including 10x Genomics, NVIDIA and the Allen Institute, maps thousands of genetic perturbations in intact mouse brain tissue and is intended as a translational resource for drug discovery and AI model training. The company said the atlas reveals context‑dependent gene effects across cell types and regions and will make the data public to accelerate therapeutic hypothesis generation. PerturbAI positions its platform to combine in vivo CRISPR perturbations with AI to improve translatability of target selection. Drug discovery groups working on neurological targets can use the atlas to prioritize genes with region‑ and cell‑type specific effects and to train models that predict in vivo consequences of genetic modulation.